Table 2

Prevalence of dAATD per 100 000 persons as of 31 December 2018

Population as of 31 December 2018cases (N)Prevalence95% CI
Overall5 819 38874912.911.9 to 13.8
By Sex*
 Females2 922 86733711.410.2 to 12.6
 Males2 896 52141214.312.9 to 15.7
By Age (years)†
 ≤12823 1268410.18.0 to 12.3
 13–18408 755266.43.9 to 8.8
 19–24461 023255.43.3 to 7.5
 25–34748 530405.33.7 to 7.0
 35–44708 4888512.09.4 to 14.5
 45–54812 43813716.814.0 to 19.6
 55–64720 66514920.717.4 to 24.0
 ≥651 136 36320317.915.4 to 20.3
By end of year†‡
 20045 489 869631.10.8 to 1.4
 20095 617 2892204.03.4 to 4.5
 20145 728 3734688.27.5 to 8.9
 20185 819 38874912.911.9 to 13.8
  • *Adjusted to the population age distribution as of 31 December 2018.

  • †Adjusted to the population sex distribution as of 31 December 2018.

  • ‡Adjusted to the age and sex distribution as of 31 December 2018.

  • AATD, alpha-1 antitrypsin deficiency; dAATD, diagnosed alpha-1 antitrypsin deficiency.